Royal Bank of Canada »

An2 Therapeutics shares owned by Royal Bank of Canada

Quarter-by-quarter ownership of An2 Therapeutics (ANTX) shares owned by Royal Bank of Canada from 13F filings

Historical chart of Royal Bank of Canada investment in An2 Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including An2 Therapeutics held by Royal Bank of Canada consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in An2 Therapeutics by Royal Bank of Canada

Quarter filed Position value Share count Share price at filing
2026-06-30 $5.0k 938 5.33
2024-06-30 $6.6k 2.8k 2.35
2023-06-30 $2.0k 186 10.75
2022-12-31 $17k 1.8k 9.58
2022-09-30 $1.0k 59 16.95

More positions owned by Royal Bank of Canada

State Str Spdr S&p 500 Etf T Tr Unit (SPY)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Rbc Cad (RY)
Alphabet Cap Stk Cl A (GOOGL)
Microsoft Corporation (MSFT)
Toronto Dominion Bk Ont Com New (TD)
Amazon (AMZN)
Ishares Tr Core S&p500 Etf (IVV)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Bank Of Montreal Cadcom (BMO)
Alphabet Cap Stk Cl C (GOOG)
Cibc Cad (CM)
Broadcom (AVGO)
JPMorgan Chase & Co. (JPM)

View all positions for Royal Bank of Canada

Top funds holding An2 Therapeutics

Vivo Capital
Commodore Capital
Millennium Management
BlackRock
Spruce Street Capital
Almitas Capital
Vanguard Capital Management
Adage Capital Partners GP
Citadel Advisors
Boxer Capital Management
Geode Capital Management
SummitTX Capital
Balyasny Asset Management
Stonepine Capital Management
Ameriprise Financial

View all funds holding An2 Therapeutics